To the full analysis
China Resources Sanjiu Medical & Pharmaceutical stock: growth
000999.SZChina Resources Sanjiu Medical & Pharmaceutical reported $4.74B in revenue for fiscal 2025, up 14.4% on the prior year, up 18.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13.5%
per year from 2006 to 2025, per share 11.9%
Earnings (Annual rate)
17.3%
per year from 2006 to 2025, per share 14%
Free cash flow (Annual rate)
15.2%
per year from 2006 to 2025, per share 13.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 18.3% | 14.9% | 13.5% |
| Revenue per share | 18.2% | 14.8% | 11.9% |
| Earnings | 16.5% | 10.6% | 17.3% |
| Earnings per share | 16.5% | 10.5% | 14.0% |
| Free cash flow | 21.5% | 16.4% | 15.2% |
| Free cash flow per share | 21.4% | 16.3% | 13.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $430.09M | $24.73M | $43.44M |
| 2007 | $509.55M | $41.96M | $56.76M |
| 2008 | $647.27M | $75M | −$13.02M |
| 2009 | $727.73M | $106.4M | $99.3M |
| 2010 | $654.62M | $122.37M | $86.72M |
| 2011 | $817.97M | $114.04M | $81.75M |
| 2012 | $1.04B | $153.13M | $106.07M |
| 2013 | $1.09B | $166.28M | $166.84M |
| 2014 | $1.09B | $155.35M | $126.45M |
| 2015 | $1.18B | $187.34M | $139.35M |
| 2016 | $1.35B | $179.63M | $155.63M |
| 2017 | $1.67B | $195.21M | $177.81M |
| 2018 | $2.01B | $214.76M | $196.59M |
| 2019 | $2.22B | $314.75M | $215.33M |
| 2020 | $2.05B | $239.57M | $240.27M |
| 2021 | $2.33B | $308.19M | $151.77M |
| 2022 | $2.71B | $367.23M | $308.15M |
| 2023 | $3.71B | $427.84M | $500.06M |
| 2024 | $4.14B | $505.06M | $541.69M |
| 2025 | $4.74B | $513.15M | $636.09M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.